ABION BIO, a Korea-based biopharmaceutical company, said it has entered into a licensing and co-development agreement worth ...

Despite the rapid growth of Korea’s biopharmaceutical market, the government's approval system to support it still relies on ...

AstraZeneca Korea is expanding the therapeutic footprint of its PARP inhibitor Lynparza (ingredient: olaparib) in gynecologic ...

Just two months after German pharma Boehringer Ingelheim secured long-delayed reimbursement for Ofev in Korea, generics are ...

Inventage Lab unveiled its next-generation obesity drug platform technology in a poster presentation at the American Diabetes ...

Calls are growing to establish a new public medical school in South Jeolla Province, as promised by President Lee Jae ...

Korea’s Vaxcellbio is joining the next wave of cell therapy contenders, backed by a government grant and a platform it says ...

The Ministry of Food and Drug Safety has approved an expanded indication for Vemlidy (ingredient: tenofovir alafenamide), ...

Siemens Healthineers Korea has signed a strategic memorandum of understanding (MOU) with Phantomics, a Korean cardiac imaging ...

The rift among resigned doctors has been widening since the new government took office.A day after Park Dan, head of the ...

The mortality rate after acute myocardial infarction (AMI) was found to be higher among self-employed insured individuals ...

ABL Bio said Tuesday that its partner I-Mab will present data from the phase 1b study of ABL111 (trademark name: Givastomig) combination therapy in a mini oral presentation at the European Society for ...